• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Applied DNA Sciences Inc.

    8/14/25 9:42:06 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary
    Get the next $APDN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    APPLIED DNA SCIENCES INC.

    (Name of Issuer)


    Common Stock, $0.001 par value

    (Title of Class of Securities)


    03815U409

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    03815U409


    1Names of Reporting Persons

    Anson Funds Management LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    TEXAS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    573,538.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    573,538.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    573,538.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.2 %
    12Type of Reporting Person (See Instructions)

    IA, PN


    SCHEDULE 13G

    CUSIP No.
    03815U409


    1Names of Reporting Persons

    Anson Management GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    TEXAS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    573,538.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    573,538.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    573,538.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.2 %
    12Type of Reporting Person (See Instructions)

    HC, OO


    SCHEDULE 13G

    CUSIP No.
    03815U409


    1Names of Reporting Persons

    Tony Moore
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    573,538.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    573,538.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    573,538.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.2 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    CUSIP No.
    03815U409


    1Names of Reporting Persons

    Anson Advisors Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CANADA (FEDERAL LEVEL)
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    573,538.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    573,538.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    573,538.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.2 %
    12Type of Reporting Person (See Instructions)

    FI, CO


    SCHEDULE 13G

    CUSIP No.
    03815U409


    1Names of Reporting Persons

    Amin Nathoo
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CANADA (FEDERAL LEVEL)
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    573,538.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    573,538.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    573,538.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.2 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    CUSIP No.
    03815U409


    1Names of Reporting Persons

    Moez Kassam
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CANADA (FEDERAL LEVEL)
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    573,538.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    573,538.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    573,538.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.2 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    APPLIED DNA SCIENCES INC.
    (b)Address of issuer's principal executive offices:

    50 HEALTH SCIENCES DRIVE, STONY BROOK, NEW YORK, 11790
    Item 2. 
    (a)Name of person filing:

    Anson Funds Management LP, Anson Management GP LLC, Mr. Tony Moore, Anson Advisors Inc., Mr. Amin Nathoo and Mr. Moez Kassam
    (b)Address or principal business office or, if none, residence:

    For Anson Funds Management LP, Anson Management GP LLC and Mr. Moore: 16000 Dallas Parkway, Suite 800 Dallas, Texas 75248 For Anson Advisors Inc., Mr. Nathoo and Mr. Kassam: 181 Bay Street, Suite 4200 Toronto, ON M5J 2T3
    (c)Citizenship:

    Anson Funds Management LP is a limited partnership organized under the laws of the State of Texas. Anson Management GP LLC is a limited liability company organized under the laws of the State of Texas. Mr. Moore is a United States citizen. Anson Advisors Inc. is a corporation organized under the laws of Ontario, Canada. Mr. Nathoo and Mr. Kassam are each Canadian citizens.
    (d)Title of class of securities:

    Common Stock, $0.001 par value
    (e)CUSIP No.:

    03815U409
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Canadian Investment Advisor
    Item 4.Ownership
    (a)Amount beneficially owned:

    Anson Funds Management LP, Anson Management GP LLC, Mr. Moore, Anson Advisors Inc., Mr. Nathoo and Mr. Kassam are the beneficial owners of 573,538 shares of Common Stock held by the Fund.
    (b)Percent of class:

    Anson Funds Management LP, Anson Management GP LLC, Mr. Moore, Anson Advisors Inc., Mr. Nathoo and Mr. Kassam are the beneficial owners of 8.2% of the outstanding shares of Common Stock, which includes shares of Common Stock underlying outstanding warrants (each, a "Warrant," and collectively, the "Warrants") held by Anson Funds Management LP, Anson Management GP LLC, Mr. Moore, Anson Advisors Inc., Mr. Nathoo and Mr. Kassam. Each Warrant includes a beneficial ownership limitation. The Warrants may not be exercised to the extent the Reporting Persons would, in the case of some of the Warrants, beneficially own more than 4.99% or 9.99% of the outstanding Common Stock. The beneficial ownership set forth herein takes into account the foregoing limitation. This percentage is determined by dividing 573,538 by 7,024,821, which is the sum of: (i) 6,497,790 shares of Common Stock issued and outstanding, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on May 15, 2025; and (ii) 527,031 the number of shares of Common Stock receivable by the Fund upon exercise of the Warrants.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Section 4(a)

     (ii) Shared power to vote or to direct the vote:

    See Section 4(a)

     (iii) Sole power to dispose or to direct the disposition of:

    See Section 4(a)

     (iv) Shared power to dispose or to direct the disposition of:

    See Section 4(a)

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    See description regarding the Fund in the introduction, which is incorporated by reference herein.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    See description of control persons of Anson Funds Management LP and Anson Advisors Inc. in the introduction, which is incorporated by reference herein.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to Anson Advisors Inc. is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution(s). I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Anson Funds Management LP
     
    Signature:/s/ Tony Moore
    Name/Title:Tony Moore, Manager
    Date:08/14/2025
     
    Anson Management GP LLC
     
    Signature:/s/ Tony Moore
    Name/Title:Tony Moore, Manager
    Date:08/14/2025
     
    Tony Moore
     
    Signature:/s/ Tony Moore
    Name/Title:Tony Moore, Manager
    Date:08/14/2025
     
    Anson Advisors Inc.
     
    Signature:/s/ Amin Nathoo
    Name/Title:Amin Nathoo, Director
    Date:08/14/2025
     
    Signature:/s/ Moez Kassam
    Name/Title:Moez Kassam, Director
    Date:08/14/2025
     
    Amin Nathoo
     
    Signature:/s/ Amin Nathoo
    Name/Title:Amin Nathoo, Director
    Date:08/14/2025
     
    Moez Kassam
     
    Signature:/s/ Moez Kassam
    Name/Title:Moez Kassam, Director
    Date:08/14/2025
    Get the next $APDN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APDN

    DatePrice TargetRatingAnalyst
    2/11/2022$8.00 → $6.00Buy
    HC Wainwright & Co.
    8/13/2021$13.00 → $11.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $APDN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates

    - Signals Start of New Commercialization Phase for LineaRx Subsidiary -- Company Negotiating GMP Supply Agreement -- Company Reaffirms Strategic Restructuring Timeline - STONY BROOK, NY / ACCESSWIRE / January 10, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the completion of the buildout of its new Good Manufacturing Practices (GMP) manufacturing facility (the "facility") within its Stony Brook, New York, headquarters and readiness to accept orders for the manufacture of LineaDNA™ IVT templates that clients can utilize for the production of mRNA clinical trial materials. The facility is undergoing fi

    1/10/25 9:00:00 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    Applied DNA Reschedules Investor Update Call in Observance of the National Day of Mourning in Recognition of the Passing of Former President Jimmy Carter

    STONY BROOK, NY / ACCESSWIRE / January 8, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it has rescheduled its Investor Update call to Thursday, February 13, 2025, to coincide with the release of its first quarter fiscal 2025 financial results.The Company originally scheduled an Investor Update call for January 9, 2025, to update shareholders on its strategic restructuring announced in December 2024 and GMP initiative. The change reflects the observance of the National Day of Mourning in recognition of the passing of former President Jimmy Carter.About Applied DNA Sciences

    1/8/25 4:30:00 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA

    - Regulatory Approval Showcases Clinical Advancement of Linea DNA™ as a Rapid and Effective Means of Producing CAR-T cell Therapies -STONY BROOK, NY / ACCESSWIRE / December 18, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, announced that the State Institute for Drug Control of the Czech Republic (SÚKL) approved an application for a Phase I clinical trial of an investigational CD123-specific autologous CAR T-cell therapy by the Institute of Hematology and Blood Transfusion (ÚHKT/Eng: IHBT) in Prague for the treatment of relapsed and/or refractory acute myeloid leukemia (AML). UHKT-CAR123-01 utilizes Applied DNA's synt

    12/18/24 9:00:00 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    $APDN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Jantzen Beth

    4 - APPLIED DNA SCIENCES INC (0000744452) (Issuer)

    3/27/23 9:30:56 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    SEC Form 4 filed by Shorrock Clay

    4 - APPLIED DNA SCIENCES INC (0000744452) (Issuer)

    3/27/23 9:30:40 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    SEC Form 4 filed by Murrah Judith

    4 - APPLIED DNA SCIENCES INC (0000744452) (Issuer)

    3/27/23 9:30:30 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    $APDN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Applied DNA Sciences Inc.

    SCHEDULE 13G/A - APPLIED DNA SCIENCES INC (0000744452) (Subject)

    8/14/25 9:42:06 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    Applied DNA Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - APPLIED DNA SCIENCES INC (0000744452) (Filer)

    8/14/25 4:16:44 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    SEC Form 10-Q filed by Applied DNA Sciences Inc.

    10-Q - APPLIED DNA SCIENCES INC (0000744452) (Filer)

    8/14/25 4:10:36 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    $APDN
    Financials

    Live finance-specific insights

    View All

    Applied DNA to Report Fourth Quarter and Fiscal Year 2024 Financial Results After Market Close on December 17, 2024; Sets Webcast and Conference Call for January 9, 2025, to Coincide with Update on GMP Manufacturing Facility Build-out

    STONY BROOK, NY / ACCESSWIRE / December 16, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its fourth quarter and fiscal year 2024 financial results after the market close on Tuesday, December 17, 2024.The Company will host a conference call for the investment community to coincide with an update on its GMP manufacturing facility build-out on Thursday, January 9, 2025, at 4:30 p.m. ET.Webcast and Conference Call Date & Time: Thursday, January 9 @ 4:30 p.m. ETDial In:Domestic callers (toll free): 844-887-9402International callers: 412-317-6798Canadian callers

    12/16/24 10:00:00 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    Applied DNA to Report Third Quarter Fiscal 2024 Financial Results on Thursday, August 8, 2024

    STONY BROOK, NY / ACCESSWIRE / August 7, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its third quarter fiscal 2024 financial results after market close on Thursday, August 8, 2024. In conjunction with this announcement, Applied DNA management will host a conference call for analysts and members of the investment community starting at 4:30 p.m. ET the same day. On this call, management will discuss the Company's financial results and recent accomplishments.Date & Time: Thursday, August 8 @ 4:30 p.m. ETDial In:Domestic callers (toll free): 844-887-9402Inter

    8/7/24 8:00:00 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    Applied DNA Announces Second Quarter Fiscal Year 2024 Financial Results

    STONY BROOK, NY / ACCESSWIRE / May 10, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced consolidated financial results for its second fiscal quarter ended March 31, 2024. The Company's Form 10-Q can be viewed at https://investors.adnas.com/sec-filings/. The Company will not host a financial webcast or call for this most recent quarterly reporting period. The Company will host an investor update call on June 12, 2024.Summary Second Quarter Fiscal 2024 Financial Results:Total revenues were approximately $930 thousand for the three-month period March 31, 2024, compared to $4.4 million for the second quarter

    5/10/24 4:05:00 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    $APDN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Applied DNA Sciences Inc.

    SC 13G - APPLIED DNA SCIENCES INC (0000744452) (Subject)

    11/14/24 5:46:25 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Applied DNA Sciences Inc.

    SC 13G/A - APPLIED DNA SCIENCES INC (0000744452) (Subject)

    11/13/24 4:15:25 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Applied DNA Sciences Inc.

    SC 13G/A - APPLIED DNA SCIENCES INC (0000744452) (Subject)

    11/7/24 10:11:34 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    $APDN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on Applied DNA Sciences with a new price target

    HC Wainwright & Co. reiterated coverage of Applied DNA Sciences with a rating of Buy and set a new price target of $6.00 from $8.00 previously

    2/11/22 6:29:21 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    HC Wainwright & Co. reiterated coverage on Applied DNA Sciences with a new price target

    HC Wainwright & Co. reiterated coverage of Applied DNA Sciences with a rating of Buy and set a new price target of $11.00 from $13.00 previously

    8/13/21 6:30:16 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    HC Wainwright & Co. reiterated coverage on Applied DNA Sciences with a new price target

    HC Wainwright & Co. reiterated coverage of Applied DNA Sciences with a rating of Buy and set a new price target of $13.00 from $14.00 previously

    4/22/21 6:37:35 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    $APDN
    Leadership Updates

    Live Leadership Updates

    View All

    Applied DNA Advances Commercialization of Linea(TM) IVT Platform, Appoints Beverly Wolgast as Executive Director of Quality and cGMP Programs

    Experienced Biopharma/Pharmaceutical Executive to Lead Implementation of cGMP-quality LineaDNA™ Capability for IVT mRNA ProductionPreviously Led Manufacturing Operations Scale-up for the BioNTech/Pfizer mRNA COVID-19 Vaccine at CDMO Division of Maravai LifeSciencesSTONY BROOK, NY / ACCESSWIRE / September 6, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the appointment of Beverly Wolgast, Ph.D., as executive director of Quality and cGMP Programs. Dr. Wolgast will oversee and manage Applied DNA's quality assurance and control and regulatory compliance spanning the Company's three business segments, incl

    9/6/23 9:00:00 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    Applied DNA Appoints Clay Shorrock as Chief Legal Officer and Executive Director of Business Development

    STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that Clay Shorrock, J.D., has rejoined the Company effective immediately to serve on the executive leadership team as Chief Legal Officer and Executive Director, Business Development. In this newly created role, Mr. Shorrock will lead Applied DNA’s legal, regulatory, IP, and business development functions. Dr. James A. Hayward, president and CEO, Applied DNA, said, “As we continue to advance the adoption of our PCR-based, LinearDNATM manufacturing platform across highly regulated markets and further devel

    4/1/21 8:00:00 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary